{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:28:28Z","timestamp":1758634108024,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T00:00:00Z","timestamp":1564444800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T00:00:00Z","timestamp":1564444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s11255-019-02246-7","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T11:02:47Z","timestamp":1564484567000},"page":"1639-1647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality"],"prefix":"10.1007","volume":"51","author":[{"given":"Ahmed Yahia","family":"Elmowafy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanzada Mohamed","family":"El Maghrabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled Farouk","family":"Eldahshan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman Fathi","family":"Refaie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Adel","family":"Elbasiony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser Elsayed","family":"Matter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazem Hamed","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamal Elsayed","family":"Shiha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5130-7286","authenticated-orcid":false,"given":"Lionel","family":"Rostaing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Adel","family":"Bakr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,30]]},"reference":[{"key":"2246_CR1","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"E Gower","year":"2014","unstructured":"Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:S45\u2013S57","journal-title":"J Hepatol"},{"key":"2246_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/apt.12551","volume":"39","author":"JM Wantuck","year":"2014","unstructured":"Wantuck JM, Ahmed A, Nguyen MH (2014) Review article. The epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 39:137\u2013147","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2246_CR3","doi-asserted-by":"publisher","first-page":"c8","DOI":"10.1159\/000090505","volume":"103","author":"I Grgurevi\u0107","year":"2006","unstructured":"Grgurevi\u0107 I, Vince A, Buljevac M, Bani\u0107 M, Jeren-Struji\u0107 B, Kes P, Kujundzi\u0107 M, Leko N, Luki\u0107 IK, Slavicek J (2006) Efficacy of interferon-alpha in the treatment of chronic hepatitis C in dialysis patients: two therapeutic protocols compared. Nephron Clin Pract 103(1):c8\u2013c11","journal-title":"Nephron Clin Pract"},{"issue":"2","key":"2246_CR4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2893.2007.00907.x","volume":"15","author":"F Fabrizi","year":"2008","unstructured":"Fabrizi F, Dixit V, Messa P, Martin P (2008) Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 15(2):79\u201388","journal-title":"J Viral Hepat"},{"issue":"2","key":"2246_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1053\/j.ajkd.2007.11.003","volume":"51","author":"CE Gordon","year":"2008","unstructured":"Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB (2008) Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 51(2):263\u2013277","journal-title":"Am J Kidney Dis"},{"key":"2246_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.07.002","author":"J Vermehren","year":"2018","unstructured":"Vermehren J, Park JS, Jacobson I, Zeuzem S (2018) Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2018.07.002 (Epub ahead of print)","journal-title":"J Hepatol"},{"issue":"2","key":"2246_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s13318-016-0341-6","volume":"42","author":"AR Polepally","year":"2017","unstructured":"Polepally AR, Badri PS, Eckert D, Mensing S, Menon RM (2017) Effects of mild and moderate renal impairment on ombitasvir, paritaprevir, ritonavir, dasabuvir, and ribavirin pharmacokinetics in patients with chronic HCV infection. Eur J Drug Metab Pharmacokinet 42(2):333\u2013339","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"7","key":"2246_CR8","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","volume":"150","author":"PJ Pockros","year":"2016","unstructured":"Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, Bernstein DE, Cohen DE, Shulman NS, Wang D, Khatri A, Abunimeh M, Podsadecki T, Lawitz E (2016) Efficacy of direct-acting antiviral combination for patients with hepatitis c virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 150(7):1590\u20131598","journal-title":"Gastroenterology"},{"issue":"1","key":"2246_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver (2017) EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66(1):153","journal-title":"J Hepatol"},{"key":"2246_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2147\/TCRM.S133983","volume":"13","author":"J Sperl","year":"2017","unstructured":"Sperl J, Frankova S, Kreidlova M, Merta D, Tothova M, Spicak J (2017) Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis. Ther Clin Risk Manag 13:733\u2013738","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"2246_CR11","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s12325-017-0506-y","volume":"34","author":"K Sato","year":"2017","unstructured":"Sato K, Chayama K, Alves K, Toyoda H, Suzuki F, Kato K, Rodrigues L Jr, Zhang X, Setze C, Pilot-Matias T, Burroughs M, Redman R, Kumada H (2017) Randomized phase 3 trial of ombitasvir\/paritaprevir\/ritonavir and ribavirin for hepatitis c virus genotype 2-infected Japanese patients. Adv Ther 34(6):1449\u20131465","journal-title":"Adv Ther"},{"issue":"1","key":"2246_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00535-017-1353-y","volume":"53","author":"G Suda","year":"2017","unstructured":"Suda G, Furusyo N, Toyoda H, Kawakami Y, Ikeda H, Suzuki M, Arataki K, Mori N, Tsuji K, Katamura Y, Takaguchi K, Ishikawa T, Tsuji K, Shimada N, Hiraoka A, Yamsaki S, Nakai M, Sho T, Morikawa K, Ogawa K, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kato K, Ueno Y, Iio E, Tanaka Y, Kurosaki M, Kumada T, Chayama K, Sakamoto N (2017) Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. J Gastroenterol 53(1):119\u2013128","journal-title":"J Gastroenterol"},{"issue":"5","key":"2246_CR13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/nep.13050","volume":"23","author":"MS Akhil","year":"2018","unstructured":"Akhil MS, Kirushnan B, Martin M, Arumugam K, Ganesh Prasad NK, Ravichandran R (2018) Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: a retrospective study. Nephrology (Carlton) 23(5):446\u2013452","journal-title":"Nephrology (Carlton)"},{"issue":"7","key":"2246_CR14","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/nep.13011","volume":"22","author":"N Morisawa","year":"2017","unstructured":"Morisawa N, Koshima Y, Kuriyama S, Dolla G, Payr\u00e9 C, Jourde-Chiche N, Van de Logt AE, Booth C, Rigby E, Lonnbro-Widgren J, Nystrom J, Mariat C, Cui Z, Wetzels JFM, Ghiggeri G, Beck LH Jr, Ronco P, Debiec H, Lambeau G (2017) Effectiveness of a fixed combination formula of ombitasvir\/paritaprevir\/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis. Nephrology 22(7):562\u2013565","journal-title":"Nephrology"},{"issue":"2","key":"2246_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ekir.2018.10.003","volume":"4","author":"Eric Lawitz","year":"2019","unstructured":"Lawitz Eric et al (2019) Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir in patients with hepatitis C virus genotype 1 or 4 infection and advanced kidney disease. Kidney Int Rep 4(2):257\u2013266","journal-title":"Kidney Int Rep"},{"issue":"S1","key":"2246_CR16","first-page":"470A","volume":"63","author":"EJ Gane","year":"2016","unstructured":"Gane EJ, Sola R, Cohen E et al (2016) Efficacy and safety of a ribavirin-free ombitasvir\/paritaprevir\/ritonavir\u2009\u00b1\u2009dasabuvir regimen in patients with severe renal impairment or end-stage renal disease and HCV genotypes 1a or 4 infection. Hepatology 63(S1):470A\u2013471A","journal-title":"Hepatology"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02246-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-019-02246-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02246-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T13:48:02Z","timestamp":1721569682000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-019-02246-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,30]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["2246"],"URL":"https:\/\/doi.org\/10.1007\/s11255-019-02246-7","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"type":"print","value":"0301-1623"},{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2019,7,30]]},"assertion":[{"value":"24 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not funded. Mansoura Urology and Nephrology Center supported full laboratory and radiology investigations for the patients. Egyptian Liver Research Institute and Hospital afforded the direct antiviral in collaboration with Egyptian Health Insurance System.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}